Stanford V regimen and concomitant highly active antiretroviral therapy is feasible and active in patients with Hodgkin's disease and HIV infection.
M
M
Spina
J
J
Gabarre
M
M
Fasan
E
E
Vaccher
U
U
Tirelli
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006678:HIV / Q000187:drug effects / Q000302:isolation & purification; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000821:virology; D006689:Hodgkin Disease / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D019380:Anti-HIV Agents; D001761:Bleomycin; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D004317:Doxorubicin; D011241:Prednisone